Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-jRCT2080222894
JPRN-jRCT2080222894UnknownPhase 3

M518101 phase III study in plaque psoriasis patients

Maruho Co.,Ltd.0 sitesStarted: June 25, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 3
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 16age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • •Patients diagnosed with plaque psoriasis

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 2Plaque psoriasis
JPRN-jRCT2080221434Maruho Co.,Ltd.
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 1Plaque psoriasis
JPRN-jRCT2080221433Maruho Co.,Ltd.
Unknown
Phase 2
M518101 phase 2b study in plaque psoriasis patients - comparison study 3Plaque psoriasis
JPRN-jRCT2080222091Maruho Co.,Ltd.
Unknown
Phase 3
A phase III study of M801801 in plaque psoriasis patientsPlaque psoriasis
JPRN-jRCT2080222104Maruho Co.,Ltd.
Completed
Phase 3
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabPlaque Psoriasis
NCT04102007AbbVie244
M518101 phase III study in plaque... | Clinical Trial